



Company Announcement no. 33/2007

To: OMX Nordic Exchange

Hørsholm, Denmark, December 20, 2007

LifeCycle Pharma Announces Agreement with Top 10 Pharmaceutical Company for the use of MeltDose® Technology

Hørsholm, Denmark, December 20, 2007; LifeCycle Pharma A/S (OMX: LCP) (the “Company” or “LCP”), an emerging specialty pharmaceutical company, today announced that it has signed a collaboration Agreement with a Top 10 pharmaceutical company (“pharma company”). Per the terms of the agreement, the pharma company will use LCP’s MeltDose® technology to conduct a preclinical feasibility study in order to investigate a new formulation of one of its product candidates. No financial terms were disclosed.

“We are very pleased that a one of the largest and most well known pharmaceutical companies has decided to use our MeltDose® technology to investigate its applicability to one of its product candidates,” stated Flemming Ornskov, President and Chief Executive Officer. “We believe it is a testament to the validity and broad application of our MeltDose® technology platform.”

About LCP’s MeltDose® Technology Platform

MeltDose® is LCP’s proprietary drug delivery platform developed for the improvement of absorption and bioavailability in oral therapeutics. The benefits of MeltDose® over other drug delivery alternatives such as conventional and nanocrystal technology include: decreased inter- and intra-individual variability; reduction of food-effect; reduction in peak to trough ratio; and reduction of administration frequency. For further information or to view the MeltDose® animation, please visit: <http://lcpharma.com/technology0/meltdosetechnologyplatform>

About LifeCycle Pharma A/S (“LCP”)

LCP is an emerging specialty pharmaceuticals company that, through innovative technologies, is able to rapidly develop a portfolio of differentiated products to meet the unique needs of key therapeutic markets and patient populations. This includes products for immunosuppression, specifically organ transplantation, and to combat certain cardiovascular diseases. By using its unique and patented delivery technology, MeltDose®, LCP is able to develop drugs with enhanced absorption and thereby

LIFECYCLE PHARMA A/S
KOGLE ALLÉ 4
DK-2970 HØRSBOLM
WWW.LIFECYCLEPHARMA.COM

TEL. +45 7033 3300
FAX +45 3613 0319
CVR. 26 52 77 67
INFO@LCPHARMA.COM

page 1 of 2



increased bioavailability. Currently, the Company has a diversified near- and medium-term pipeline, including a product ready for US commercialization, five product candidates in clinical trials and three in preclinical stages of development. LCP is listed on the OMX Nordic Exchange under the trading symbol (OMX: LCP). For further information, please visit www.lcpharma.com.

Contact:

LifeCycle Pharma A/S
Michael Wolff Jensen, +45 4074-6244
EVP and CFO
MWJ@lcpharma.com

or

Francesca M. DeMartino
Director, Investor Relations & Corporate Communications
(917) 747-4938; FDM@lcpharma.com

LIFECYCLE PHARMA A/S
KOGLE ALLÉ 4
DK-2970 HØRSBOLM
WWW.LIFECYCLEPHARMA.COM

TEL. +45 7033 3300
FAX +45 3613 0319
CVR. 26 52 77 67
INFO@LCPHARMA.COM

page 2 of 2